← Leaderboards
David E Fisher
Massachusetts General Hospital
$28,420,496
Attributed
$28,420,496
Total exposure
18
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$48,301,851 · 19
By mechanism
P01$25,326,804 · 7
R01$21,404,407 · 8
RC1$988,616 · 1
R21$410,619 · 1
R03$87,173 · 1
P30$84,232 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Melanoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
- Richard L Schilsky · University Of Chicago$108,377,382
- Larry Arthur$59,113,709
- Charles A Coltman · Southwest Oncology Group$55,198,633
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
- Meenhard Herlyn · University Of Pennsylvania$46,448,742
Research focus
MelanomaPathway InteractionsMelanocyteGeneticSignal TransductionGenesGenetic TranscriptionExhibitsOncogenesMalignant NeoplasmsBaseBehaviorResistanceOncogenicMouse ModelTumorMediatingPre-ClinicalResponseIn VitroSkinFundingImmuneReporting
Grant awards (110)
Targetable epigenetic and transcriptional mechanisms in melanoma thatshape the microenvironment$2,734,241
P01 · FY2025 · CA · contact PI
Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting$642,266
P01 · FY2025 · CA · contact PI
MITF from control of pigmentation to melanoma risk$484,419
R01 · FY2025 · AR · contact PI
Therapeutic strategies for treatment of giant congenital melanocytic nevi$463,165
R01 · FY2025 · AR · contact PI
Admin Core$205,420
P01 · FY2025 · CA · contact PI
Targetable epigenetic and transcriptional mechanisms in melanoma thatshape the microenvironment$2,800,993
P01 · FY2024 · CA · contact PI
Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting$658,720
P01 · FY2024 · CA · contact PI
MITF from control of pigmentation to melanoma risk$519,228
R01 · FY2024 · AR · contact PI
Therapeutic strategies for treatment of giant congenital melanocytic nevi$496,338
R01 · FY2024 · AR · contact PI
Admin Core$205,202
P01 · FY2024 · CA · contact PI
Therapeutic strategies for treatment of giant congenital melanocytic nevi$96,504
R01 · FY2024 · AR · contact PI
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment$1,428,421
P01 · FY2023 · CA · contact PI
MITF from control of pigmentation to melanoma risk$552,287
R01 · FY2023 · AR · contact PI
Therapeutic strategies for treatment of giant congenital melanocytic nevi$511,688
R01 · FY2023 · AR · contact PI
Project 1: Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting$330,547
P01 · FY2023 · CA · contact PI
Administrative Core$114,256
P01 · FY2023 · CA · contact PI
MITF from control of pigmentation to melanoma risk$90,000
R01 · FY2023 · AR · contact PI
Program 35: Melanoma$42,116
P30 · FY2023 · CA · contact PI
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment$1,430,472
P01 · FY2022 · CA · contact PI
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.$366,076
R01 · FY2022 · CA · contact PI
MITF: master regulator of melanocyte development, pigmentation, and UV-related skin disease risk$358,498
R01 · FY2022 · AR · contact PI
Project 1: Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting$332,593
P01 · FY2022 · CA · contact PI
Administrative Core$114,256
P01 · FY2022 · CA · contact PI
Program 35: Melanoma$42,116
P30 · FY2022 · CA · contact PI
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment$1,461,713
P01 · FY2021 · CA · contact PI
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.$373,547
R01 · FY2021 · CA · contact PI
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi$353,411
R01 · FY2021 · AR · contact PI
MITF: master regulator of melanocyte development, pigmentation, and UV-related skin disease risk$351,255
R01 · FY2021 · AR · contact PI
Project 1: Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting$341,431
P01 · FY2021 · CA · contact PI
Administrative Core$116,589
P01 · FY2021 · CA · contact PI
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment$1,463,720
P01 · FY2020 · CA · contact PI
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.$373,547
R01 · FY2020 · CA · contact PI
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi$364,342
R01 · FY2020 · AR · contact PI
MITF: master regulator of melanocyte development, pigmentation, and UV-related skin disease risk$362,119
R01 · FY2020 · AR · contact PI
Project 1: Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting$343,436
P01 · FY2020 · CA · contact PI
Administrative Core$116,589
P01 · FY2020 · CA · contact PI
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment$1,516,688
P01 · FY2019 · CA · contact PI
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi$364,342
R01 · FY2019 · AR · contact PI
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.$362,340
R01 · FY2019 · CA · contact PI
MITF: master regulator of melanocyte development, pigmentation, and UV-related skin disease risk$362,119
R01 · FY2019 · AR · contact PI
Project 1: Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting$345,406
P01 · FY2019 · CA · contact PI
Administrative Core$116,589
P01 · FY2019 · CA · contact PI
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.$373,547
R01 · FY2018 · CA · contact PI
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi$364,342
R01 · FY2018 · AR · contact PI
MITF: master regulator of melanocyte development, pigmentation, and UV-related skin disease risk$362,119
R01 · FY2018 · AR · contact PI
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma$1,407,704
P01 · FY2017 · CA · contact PI
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi$364,342
R01 · FY2017 · AR · contact PI
The MITF transcriptional network: melanoma risk and carcinogenesis$342,200
R01 · FY2017 · AR · contact PI
Combinatorial Approaches to Overcoming Resistance to BRAF(V600E) Targeted Thera$247,819
P01 · FY2017 · CA · contact PI
Administrative Core$122,819
P01 · FY2017 · CA · contact PI
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma$1,407,704
P01 · FY2016 · CA · contact PI
The MITF transcriptional network: melanoma risk and carcinogenesis$342,200
R01 · FY2016 · AR · contact PI
Combinatorial Approaches to Overcoming Resistance to BRAF(V600E) Targeted Thera$199,970
P01 · FY2016 · CA · contact PI
Administrative Core$74,970
P01 · FY2016 · CA · contact PI
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma$1,405,454
P01 · FY2015 · CA · contact PI
Role of beta-endorphin in cancer therapy induced fatigue$352,310
R01 · FY2015 · CA · contact PI
The MITF transcriptional network: melanoma risk and carcinogenesis$342,200
R01 · FY2015 · AR · contact PI
Combinatorial Approaches to Overcoming Resistance to BRAF(V600E) Targeted Thera$199,970
P01 · FY2015 · CA · contact PI
Administrative Core$74,970
P01 · FY2015 · CA · contact PI
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma$1,363,291
P01 · FY2014 · CA · contact PI
The MITF transcriptional network: melanoma risk and carcinogenesis$342,200
R01 · FY2014 · AR · contact PI
Role of beta-endorphin in cancer therapy induced fatigue$342,164
R01 · FY2014 · CA · contact PI
Combinatorial Approaches to Overcoming Resistance to BRAF(V600E) Targeted Thera$193,972
P01 · FY2014 · CA · contact PI
Development of next-generation cancer functional diagnostics$183,549
R21 · FY2014 · CA · contact PI
Administrative Core$72,719
P01 · FY2014 · CA · contact PI
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma$1,460,954
P01 · FY2013 · CA · contact PI
The MITF transcriptional network: melanoma risk and carcinogenesis$342,200
R01 · FY2013 · AR · contact PI
Role of beta-endorphin in cancer therapy induced fatigue$331,979
R01 · FY2013 · CA · contact PI
Development of next-generation cancer functional diagnostics$227,070
R21 · FY2013 · CA · contact PI
Combinatorial Approaches to Overcoming Resistance to BRAF(V600E) Targeted Thera$199,970
P01 · FY2013 · CA · contact PI
Administrative Core$74,970
P01 · FY2013 · CA · contact PI
Role of beta-endorphin in cancer therapy induced fatigue$353,580
R01 · FY2012 · CA · contact PI
Molecular mechanisms of notch signaling in maintenance of melanocyte stem cells$291,279
R01 · FY2012 · AR · contact PI
Mitf: A Master Gene for Melanocyte Development$404,198
R01 · FY2011 · AR · contact PI
Role of beta-endorphin in cancer therapy induced fatigue$353,979
R01 · FY2011 · CA · contact PI
Molecular mechanisms of notch signaling in maintenance of melanocyte stem cells$310,529
R01 · FY2011 · AR · contact PI
Identification of small molecule modulators of MITF$42,923
R03 · FY2011 · DA · contact PI
Targeted induction of true sunless tanning for skin cancer preventation$489,308
RC1 · FY2010 · AR · contact PI
Mitf: A Master Gene for Melanocyte Development$360,866
R01 · FY2010 · AR · contact PI
Identification of small molecule modulators of MITF$44,250
R03 · FY2010 · DA · contact PI
Mitf: A Master Gene for Melanocyte Development$33,365
R01 · FY2010 · AR · contact PI
Targeted induction of true sunless tanning for skin cancer preventation$499,308
RC1 · FY2009 · AR · contact PI
Mitf: A Master Gene for Melanocyte Development$363,949
R01 · FY2009 · AR · contact PI
Mitf-Signal Responsive Transcription in Osteoclasts$288,652
R01 · FY2009 · AR · contact PI
Mitf-Signal Responsive Transcription in Osteoclasts$237,730
R01 · FY2008 · AR · contact PI
Mitf: A Master Gene for Melanocyte Development$198,022
R01 · FY2008 · AR · contact PI
The MiT Transcription Factor in Pediatric Malignancies$177,826
R01 · FY2008 · CA · contact PI
Mitf: A Master Gene for Melanocyte Development$156,376
R01 · FY2008 · AR · contact PI
The MiT Transcription Factor in Pediatric Malignancies$121,321
R01 · FY2008 · CA · contact PI
Mitf: A Master Gene for Melanocyte Development$361,630
R01 · FY2007 · AR · contact PI
The MiT Transcription Factor in Pediatric Malignancies$299,147
R01 · FY2007 · CA · contact PI
Mitf-Signal Responsive Transcription in Osteoclasts$283,696
R01 · FY2007 · AR · contact PI
The MiT Transcription Factor in Pediatric Malignancies$308,081
R01 · FY2006 · CA · contact PI
Mitf-Signal Responsive Transcription in Osteoclasts$292,169
R01 · FY2006 · AR · contact PI
MI--A MASTER GENE FOR MELANOCYTE DEVELOPMENT$331,350
R01 · FY2005 · AR
The MiT Transcription Factor in Pediatric Malignancies$315,495
R01 · FY2005 · CA
Mitf-Signal Responsive Transcription in Osteoclasts$299,200
R01 · FY2005 · AR
MI--A MASTER GENE FOR MELANOCYTE DEVELOPMENT$331,350
R01 · FY2004 · AR
The MiT Transcription Factor in Pediatric Malignancies$315,495
R01 · FY2004 · CA
MI--A MASTER GENE FOR MELANOCYTE DEVELOPMENT$331,350
R01 · FY2003 · AR
TAILORING ANTICANCER THERAPY TO LOSS OF P53$291,070
R01 · FY2003 · CA
MI--A MASTER GENE FOR MELANOCYTE DEVELOPMENT$332,120
R01 · FY2002 · AR
MI--SIGNAL RESPONSIVE TRANSCRIPTION IN OSTEOCLASTS$301,176
R01 · FY2002 · AR
TAILORING ANTICANCER THERAPY TO LOSS OF P53$284,632
R01 · FY2002 · CA
MI--A MASTER GENE FOR MELANOCYTE DEVELOPMENT$333,046
R01 · FY2001 · AR
MI--SIGNAL RESPONSIVE TRANSCRIPTION IN OSTEOCLASTS$292,406
R01 · FY2001 · AR
TAILORING ANTICANCER THERAPY TO LOSS OF P53$278,381
R01 · FY2001 · CA
MI--SIGNAL RESPONSIVE TRANSCRIPTION IN OSTEOCLASTS$283,887
R01 · FY2000 · AR
TAILORING ANTICANCER THERAPY TO LOSS OF P53$272,313
R01 · FY2000 · CA
MI--A MASTER GENE FOR MELANOCYTE DEVELOPMENT$207,713
R01 · FY2000 · AR